Literature DB >> 50353

Immunochemical characterization of the anti-RNA antibodies found in scleroderma and systemic lupus erythematosus. I. Differences in reactivity with Poly (U) and Poly-(A) Poly (U).

D Alarcón-Segovia, E Fishbein.   

Abstract

In a previous study, all 40 sera from patients with scleroderma, 20 of 40 sera from SLE patients, but none of 40 sera from normal controls, were found to have antibodies to ssRNA. All scleroderma sera were also found to react with HSA-coupled uridine and UMP and their reaction with HSA-coupled uridine and UMP and their reaction with ssRNA could be inhibited by uracil, uridine, and UMP. To characterize further these uracil-specific anti-RNA antibodies found in scleroderma and compare them with the anti-RNA antibodies found in SLE, we tested their reactivity with Poly (U) and with Poly (A)-Poly (U) and all but one failed to react with Poly (A)-Poly (U). This same serum was the only one in which the reaction with Poly (U) could not be inhibited with uracil. Reactivity of SLE sera was strikingly different from that found in scleroderma sera. Seventeen of 34 SLE sera studied reacted with ssRNA but only four of these reacted with Poly (U). Conversely, two SLE sera that reacted with Poly (U) did not react with ssRNA. Fifteen reacted with Poly (A)-Poly (U) and only two of these failed to react with ssRNA. Five SLE sera which were reactive with ssRNA did not precipitate with Poly (A)-Poly (U). All SLE sera which reacted with Poly (U) could be inhibited with uracil, although less effectively than in scleroderma. Reactivity with Poly (A)-Poly )U) was not inhibited with uracil nor with adenosine. These findings confirm that antibodies to RNA that are found in scleroderma are directed to uracil and thus specific to ssRNA, whereas RNA antibodies found in SLE sera are heterogeneous and directed to either the base, to the site of union of the base and sugar moiety to the ribose backbone, or to the helical structure of double stranded RNA. These differences and the respective antigenic specificities of these anti-RNA antibodies found in scleroderma and SLE may be theoretically important.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 50353

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  B-cell epitopes of RNA autoantigens.

Authors:  R M Hoet; W J van Venrooij
Journal:  Mol Biol Rep       Date:  1992-06       Impact factor: 2.316

Review 2.  Pathogenesis of scleroderma: the interrelationship of the immune and vascular hypotheses.

Authors:  E M Sternberg
Journal:  Surv Immunol Res       Date:  1985

3.  Serological markers in progressive systemic sclerosis: clinical correlations.

Authors:  L J Catoggio; R M Bernstein; C M Black; G R Hughes; P J Maddison
Journal:  Ann Rheum Dis       Date:  1983-02       Impact factor: 19.103

4.  Analysis of antibodies to RNA in patients with systemic lupus erythematosus and other autoimmune rheumatic diseases.

Authors:  F Blanco; J Kalsi; D A Isenberg
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

5.  Disease activity in systemic lupus erythematosus related to a range of antibodies binding DNA and synthetic polynucleotides.

Authors:  D A Isenberg; C Dudeney; W Williams; A Todd-Pokropek; B D Stollar
Journal:  Ann Rheum Dis       Date:  1988-09       Impact factor: 19.103

6.  Cutaneous antigen-stimulating lymphokine production by lymphocytes of patients with progressive systemic sclerosis (scleroderma).

Authors:  H Kondo; B S Rabin; G P Rodnan
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

7.  Immunopathology of the renal vascular lesion of progressive systemic sclerosis (scleroderma).

Authors:  D Lapenas; G P Rodnan; T Cavallo
Journal:  Am J Pathol       Date:  1978-05       Impact factor: 4.307

8.  Monocyte-induced inhibition of lymphocyte response to phytohaemagglutinin in progressive systemic sclerosis.

Authors:  M D Lockshin; J A Markenson; L Fuzesi; S Kazanjian-Aram; C Joachim; M Ordene
Journal:  Ann Rheum Dis       Date:  1983-02       Impact factor: 19.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.